We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Guided Therapeutics - GTHP
An SI Board Since October 1997
Posts SubjectMarks Bans Symbol
118 5 0 GTHP
Emcee:  caly Type:  Unmoderated
Guided Therapeutics GTHP.OB

Company Website:

Press Releases:

SEC Filings:

FDA Medical Devices page:

Slide presentation from a small cap conference Jan. 2011:[Compatibility%20Mode].pdf

Shares Outstanding: 49,056,347 as of 10/31/2011
Shares Outstanding: 48,448,685 as of 05/10/2010
Shares Outstanding: 46,480,950 as of 11/01/2010
Shares Outstanding: 42,516,855 as of 07/30/2010
Shares Outstanding: 41,698,396 as of 04/30/2010
Shares Outstanding: 19,614,975 as of 02/25/2010
Shares Outstanding: 17,470,656 as of 11/09/2009
Shares Outstanding: 16,852,823 as of 08/14/2009
Shares Outstanding: 15,998,790 as of 05/22/2009
Shares Outstanding: 11,948,631 as of 04/09/2007

** On February 26, 2010, the Company held a special meeting of stockholders to approve an amendment to the Company’s certificate of incorporation to reclassify the series A convertible preferred stock into common stock and warrants to purchase shares of common stock. As a result, all 242,576 outstanding shares of series A convertible preferred stock and accrued dividends were reclassified into 8,084,139 shares of common stock and warrants to purchase an additional 2,799,327 shares of common stock. Upon this reclassification, approximately $9.1 million in outstanding 2007 Notes was automatically converted into 14.0 million shares of common stock.

Float: 28,292,659 as of 12/01/2010 per the company
Float: 31.21M as of 12/17/2010 per Yahoo
Float: 12.45M as of 3/17/2010 per Yahoo

Warrants and Options

We have issued warrants to purchase our common stock from time to time in connection with certain financing and other arrangements. As of November 30, 2011, there are warrants exercisable for an aggregate of 31,749,910 shares of common stock outstanding. Warrants exercisable for 28,897,934 of these shares have an exercise price of $0.65 per share and expire on March 1, 2013, warrants exercisable for 285,186 of these shares have an exercise price of $1.05 per share and expire on November 20, 2016 and warrants exercisable for 2,560,000 of these shares have an exercise price of $0.01 and expire on March 1, 2013. All outstanding warrant agreements provide for antidilution adjustments in the event of certain mergers, consolidations, reorganizations, recapitalizations, stock dividends, stock splits or other changes in our corporate structure. The shares of common stock to be offered hereby are issuable upon exercise of these warrants.

As of November 30, 2011, we have issued options to purchase a total of 5,700,667 shares of our common stock pursuant to various equity incentive plans, at a weighted average exercise price of $0.53 per share. Recommendations for option grants under our equity incentive plans are made by the compensation committee of our board, subject to ratification by the full board. The compensation committee may issue options with varying vesting schedules, but all options granted pursuant to our equity incentive plans must be exercised within ten years from the date of grant.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
118Guided Therapeutics Notified of CE Mark Approval for LuViva® Advanced Cervicaly-7/18/2012
117At least things are moving ahead in Canada... Published: Tuesday, Jan. 31, 2012caly-1/31/2012
116Guided Therapeutics Provides Update on PMA Application for LuViva® Advancedcaly-1/20/2012
115Just noticed that it took 6 days for the last notice to be posted to the websitecaly-1/20/2012
114Medical Devices News page at the FDA. Nothing yet. fda.govcaly-1/20/2012
113Today's the day they were supposed to hear from FDA...according to the FDA.caly-1/20/2012
112Weak hands being shaken or bad news leaking? Place your bets!caly-1/11/2012
111Health Canada Approves Guided Therapeutics' LuViva(TM) Advanced Cervical Scacaly-12/14/2011
110Be it a coincidence or not, January, the assumed month of FDA approval, is Natiocaly-12/9/2011
109National Cancer Institute Designates Guided Therapeutics’ LuViva™ Advanced Cervicaly-12/9/2011
108Form 8-K for GUIDED THERAPEUTICS INC 28-Nov-2011 Entry into a Material Definitcaly-11/28/2011
107Guided Therapeutics Reports Update on FDA Review of LuViva™ Advanced Cervical Sccaly-11/2/2011
106Former Delta Air Lines CEO Named Guided Therapeutics Chairman Press Release Sourcaly-8/17/2011
105The rescheduled meeting of the Ob/Gyn Panel is now off the schedule. It sounds caly-7/15/2011
104We might be starting to see PPS creep as September nears. Note the FDA Panel mecaly-7/6/2011
103projectreporter.nih.govcaly-6/20/2011 On June 1, 2011, William Zachary, the Chairman of the Company's boacaly-6/3/2011
101HPV test beats Pap for cervical cancer screening By MARILYNN MAcaly-5/18/2011
10010Q Filed: LuViva™ (formerly LightTouch)caly-5/16/2011
99Guided Therapeutics to Unveil Cervical Disease Detection Technology New Design acaly-4/28/2011
98LOL! You're absolutely right. :)caly-4/26/2011
97Put a beard on him, and he's Conan O'Brien.Jeffrey Beckman-4/26/2011 Posted April 24, 2011 By Richard Rabicoff NORCROSS --caly-4/25/2011
95Konica Minolta Opto, Inc. Extends Product Development Licensing Agreement with $caly-3/30/2011
94The previously scheduled May meeting of the FDA's Ob/Gyn Devices Advisory Pacaly-3/27/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):